25 October 2013



Centralised Company Announcements Platform Australian Stock Exchange 10th floor, 20 Bond Street Sydney NSW 2000

Dear Sir / Madam,

#### Appendix 3B – Rights Issue Shares

The Board of Directors for Allied Healthcare Group would like to thank shareholders for their support during the recent Rights Issue. In total the company received applications for over \$17 million for the offering.

The Board of Directors of Allied Healthcare Group Ltd (ASX: AHZ) hereby announce that 208,804,017 fully paid ordinary shares have now been allotted upon the clearing of receipts totalling \$10,440,200.85.

Refer to the attached Appendix 3B

The company looks forward to its continued growth with a number of major milestones anticipated in the coming 12 months.

Refund cheques for oversubscriptions will be posted to shareholders early to mid-next week.

If you have any questions in relation to your entitlement under the Offer, please contact:

Computershare Investor Services Pty Limited **Telephone:** 1300 850 505 (within Australia) +61 (0)3 9415 4000 (outside Australia)

Yours sincerely For and on behalf of Allied Healthcare Group Limited

Stephen Mann Company Secretary



ABN 35 088 221 078 Level 1, 197 Adelaide Terrace Perth Western Australia 6000

PO Box 6879 East Perth Western Australia 6892

T +61 (0) 8 9385 5038 F +61 (0) 8 9385 5028 E info@alliedhealthcaregroup.com.au www.alliedhealthcaregroup.com.au

*Rule 2.7, 3.10.3, 3.10.4, 3.10.5* Appendix 3B

#### New issue announcement,

## application for quotation of additional securities

### and agreement

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 01/07/96 Origin: Appendix 5 Amended 01/07/98, 01/09/99, 01/07/00, 30/09/01, 11/03/02, 01/01/03, 24/10/05, 01/08/12

Name of entity

#### ALLIED HEALTHCARE GROUP LIMITED

ABN

35 088 221 078

We (the entity) give ASX the following information.

### Part 1 - All issues

You must complete the relevant sections (attach sheets if there is not enough space).

1 +Class of +securities issued or to be issued Ordinary shares fully paid

Rights Issue - 208,804,017

Ordinary shares fully paid ranking equally with existing ordinary shares fully paid.

- 2 Number of \*securities issued or to be issued (if known) or maximum number which may be issued
- Principal of the terms 3 +securities (eg, if options, exercise price and expiry date; if partly paid +securities, the amount outstanding and due dates for payment; if +convertible securities, the conversion price and dates for conversion)

<sup>+</sup> See chapter 19 for defined terms.

4 Do the \*securities rank equally in all respects from the date of allotment with an existing \*class of quoted \*securities?

If the additional securities do not rank equally, please state:

- the date from which they do
- the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment
- the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment
- 5 Issue price or consideration

#### 6 Purpose of the issue (If issued as consideration for the acquisition of assets, clearly identify those assets)

Rights Issue - \$0.05 per share

The purpose of the Rights Issue is outlined in the Company's announcement dated 23 September 2013

6a Is the entity an <sup>+</sup>eligible entity that has obtained security holder approval under rule 7.1A?

> If Yes, complete sections 6b – 6h in relation to the +securities the subject of this Appendix 3B, and comply with section 6i

- 6b The date the security holder resolution under rule 7.1A was passed
- 6c Number of \*securities issued without security holder approval under rule 7.1
- 6d Number of \*securities issued with security holder approval under rule 7.1A

20 November 2012

N/A

Yes

N/A

<sup>+</sup> See chapter 19 for defined terms.

- 6e Number of \*securities issued with security holder approval under rule 7.3, or another specific security holder approval (specify date of meeting)
- 6f Number of securities issued under an exception in rule 7.2
- 6g If securities issued under rule 7.1A, was issue price at least 75% of 15 day VWAP as calculated under rule 7.1A.3? Include the issue date and both values. Include the source of the VWAP calculation.
- 6h If securities were issued under rule 7.1A for non-cash consideration, state date on which valuation of consideration was released to ASX Market Announcements
- 6i Calculate the entity's remaining issue capacity under rule 7.1 and rule 7.1A – complete Annexure 1 and release to ASX Market Announcements
- 7 Dates of entering <sup>+</sup>securities into uncertificated holdings or despatch of certificates
- 8 Number and <sup>+</sup>class of all <sup>+</sup>securities quoted on ASX (*including* the securities in section 2 if applicable)

Number	<sup>+</sup> Class
1,252,825,878	Ordinary Shares

208,804,017 (Exception 1)

N/A

N/A

N/A

Listing Rule 7.1 capacity: 89,695,657

Listing Rule 7.1A capacity: 116,741,003

7 October 2013

		Number	+Class
9	Number and <sup>+</sup> class of all <sup>+</sup> securities not quoted on ASX	15,300,000	18/06/18 \$0.095 options
( <i>including</i> the securities in section 2 if applicable)	2,000,000	01/03/18 \$0.06 options	
		2,466,667	18/05/17 \$0.06 options
		6,500,000	10/7/16 \$0.06 options
		53,350,000	10/7/16 \$0.06 options
		5,000,000	22/10/14 \$0.10 options
10	Dividend policy (in the case of a trust, distribution policy) on the increased capital (interests)	N/A	

# Part 2 - Bonus issue or pro rata issue

11	Is security holder approval required?	No
12	Is the issue renounceable or non- renounceable?	Non-renounceable
13	Ratio in which the <sup>+</sup> securities will be offered	1 share for every 5 shares held at the record date
14	<sup>+</sup> Class of <sup>+</sup> securities to which the offer relates	Ordinary Shares
15	<sup>+</sup> Record date to determine entitlements	1 October 2013
16	Will holdings on different registers (or subregisters) be aggregated for calculating entitlements?	No
17	Policy for deciding entitlements in relation to fractions	Any fractional entitlement will be rounded down to the nearest whole share

<sup>+</sup> See chapter 19 for defined terms.

will not be sent new issue documents Note: Security holders must be told how their entitlements are to be dealt with. Cross reference: rule 7.7. 18 October 2013 Closing date for receipt of acceptances or renunciations **RBS Morgans Corporate Limited** Names of any underwriters 20 Amount of any underwriting fee 5% or commission Names of any brokers to the **RBS** Morgans Corporate Limited issue Fee or commission payable to N/A the broker to the issue N/A Amount of any handling fee payable to brokers who lodge acceptances or renunciations on behalf of +security holders If the issue is contingent on N/A +security holders' approval, the date of the meeting 3 October 2013 Date entitlement and acceptance form and prospectus or Product Disclosure Statement will be sent to persons entitled If the entity has issued options, 23 September 2013 and the terms entitle option participate holders to on exercise, the date on which notices will be sent to option holders Date rights trading will begin (if | N/A applicable) N/A Date rights trading will end (if applicable)

21

Names of countries in which the

entity has +security holders who

18

19

- 22
- 23
- 24
- 25
- 26
- 27
- 28
- 29

Appendix 3B Page 6

- 30 How do <sup>+</sup>security holders sell N/A their entitlements *in full* through a broker?
- 31 How do <sup>+</sup>security holders sell part of their entitlements through a broker and accept for the balance?
- 32 How do <sup>+</sup>security holders dispose of their entitlements (except by sale through a broker)?

33 <sup>+</sup>Despatch date

25 October 2013

N/A

N/A

## Part 3 - Quotation of securities

You need only complete this section if you are applying for quotation of securities

- 34 Type of securities (*tick one*)
- (a) Securities described in Part 1
- (b)

All other securities

Example: restricted securities at the end of the escrowed period, partly paid securities that become fully paid, employee incentive share securities when restriction ends, securities issued on expiry or conversion of convertible securities

#### Entities that have ticked box 34(a)

#### Additional securities forming a new class of securities

Tick to indicate you are providing the information or documents

35		If the *securities are *equity securities, the names of the 20 largest holders of the additional *securities, and the number and percentage of additional *securities held by those holders
		N/A
36		If the *securities are *equity securities, a distribution schedule of the additional *securities setting out the number of holders in the categories
		1 - 1,000
		1,001 - 5,000
		5,001 - 10,000
		10,001 - 100,000
		100,001 and over
		N/A
37		A copy of any trust deed for the additional <sup>+</sup> securities
	N/A	

<sup>+</sup> See chapter 19 for defined terms.

# Entities that have ticked box 34(b)

38	Number of securities for which <sup>+</sup> quotation is sought	N/A	
39	Class of <sup>+</sup> securities for which quotation is sought	N/A	
40	Do the <sup>+</sup> securities rank equally in all respects from the date of allotment with an existing <sup>+</sup> class of quoted <sup>+</sup> securities?	N/A	
	<ul> <li>If the additional securities do not rank equally, please state:</li> <li>the date from which they do</li> <li>the extent to which they participate for the next dividend, (in the case of a trust, distribution) or interest payment</li> <li>the extent to which they do not rank equally, other than in relation to the next dividend, distribution or interest payment</li> </ul>		
41	Reason for request for quotation now Example: In the case of restricted securities, end of restriction period	N/A	
	(if issued upon conversion of another security, clearly identify that other security)		
42	Number and <sup>+</sup> class of all <sup>+</sup> securities quoted on ASX ( <i>including</i> the securities in clause 38)	Number N/A	+Class N/A

<sup>+</sup> See chapter 19 for defined terms.

### **Quotation agreement**

- <sup>1</sup> <sup>+</sup>Quotation of our additional <sup>+</sup>securities is in ASX's absolute discretion. ASX may quote the <sup>+</sup>securities on any conditions it decides.
- 2 We warrant the following to ASX.
  - The issue of the <sup>+</sup>securities to be quoted complies with the law and is not for an illegal purpose.
  - There is no reason why those +securities should not be granted +quotation.
  - An offer of the <sup>+</sup>securities for sale within 12 months after their issue will not require disclosure under section 707(3) or section 1012C(6) of the Corporations Act.

Note: An entity may need to obtain appropriate warranties from subscribers for the securities in order to be able to give this warranty

- Section 724 or section 1016E of the Corporations Act does not apply to any applications received by us in relation to any \*securities to be quoted and that no-one has any right to return any \*securities to be quoted under sections 737, 738 or 1016F of the Corporations Act at the time that we request that the \*securities be quoted.
- If we are a trust, we warrant that no person has the right to return the <sup>+</sup>securities to be quoted under section 1019B of the Corporations Act at the time that we request that the <sup>+</sup>securities be quoted.
- 3 We will indemnify ASX to the fullest extent permitted by law in respect of any claim, action or expense arising from or connected with any breach of the warranties in this agreement.
- 4 We give ASX the information and documents required by this form. If any information or document not available now, will give it to ASX before <sup>+</sup>quotation of the <sup>+</sup>securities begins. We acknowledge that ASX is relying on the information and documents. We warrant that they are (will be) true and complete.

Sign here:

2

Date: .25 October 2013

Company secretary

Print name:

..Stephen Mann.....

== == == == ==

Appendix 3B – Annexure 1

# Calculation of placement capacity under rule 7.1 and rule 7.1A for $^+$ eligible entities

Introduced 01/08/12

## Part 1

Rule 7.1 – Issues exceeding 15% of capital Step 1: Calculate "A", the base figure from which the placement capacity is calculated		
Add the following:		
• Number of fully paid ordinary securities issued in that 12 month period under an exception in rule 7.2	362,047,350	
<ul> <li>Number of fully paid ordinary securities issued in that 12 month period with shareholder approval</li> </ul>	3,617,368	
<ul> <li>Number of partly paid ordinary securities that became fully paid in that 12 month period</li> </ul>		
<ul> <li>Note:</li> <li>Include only ordinary securities here – other classes of equity securities cannot be added</li> <li>Include here (if applicable) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
<i>Subtract</i> the number of fully paid ordinary securities cancelled during that 12 month period	Nil	
"A"	1,167,410,031	

Step 2: Calculate 15% of "A"		
"B"	0.15 [Note: this value cannot be changed]	
<i>Multiply</i> "A" by 0.15	175,111,504	
Step 3: Calculate "C", the amount of that has already been used	of placement capacity under rule 7.1	
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period <i>not counting</i> those issued:	85,415,847	
Under an exception in rule 7.2		
Under rule 7.1A		
• With security holder approval under rule 7.1 or rule 7.4		
<ul> <li>Note:</li> <li>This applies to equity securities, unless specifically excluded – not just ordinary securities</li> <li>Include here (if applicable ) the securities the subject of the Appendix 3B to which this form is annexed</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>		
"C"	85,415,847	
Step 4: Subtract "C" from ["A" x "B"] to calculate remaining placement capacity under rule 7.1		
"A" x 0.15 Note: number must be same as shown in Step 2	175,111,504	
Subtract "C"	85,415,847	
Note: number must be same as shown in Step 3		
<i>Total</i> ["A" x 0.15] – "C"	89,695,657	
	[Note: this is the remaining placement capacity under rule 7.1]	

Rule 7.1A – Additional placement capacity for eligible entities			
Step 1: Calculate "A", the base figure from which the placement capacity is calculated			
<b>"A"</b> Note: number must be same as shown in Step 1 of Part 1	1,167,410,031		
Step 2: Calculate 10% of "A"			
"D"	0.10 Note: this value cannot be changed		
<i>Multiply</i> "A" by 0.10	116,741,003		
Step 3: Calculate "E", the amount of placement capacity under rule 7.1A that has already been used			
<i>Insert</i> number of equity securities issued or agreed to be issued in that 12 month period under rule 7.1A	Nil		
<ul> <li>Notes:</li> <li>This applies to equity securities – not just ordinary securities</li> <li>Include here – if applicable – the securities the subject of the Appendix 3B to which this form is annexed</li> <li>Do not include equity securities issued under rule 7.1 (they must be dealt with in Part 1), or for which specific security holder approval has been obtained</li> <li>It may be useful to set out issues of securities on different dates as separate line items</li> </ul>			
"E"	Nil		

Step 4: Subtract "E" from ["A" x "D"] to calculate remaining placement capacity under rule 7.1A		
"A" x 0.10 Note: number must be same as shown in Step 2	116,741,003	
<i>Subtract</i> "E" <i>Note: number must be same as shown in</i> <i>Step 3</i>	Nil	
<i>Total</i> ["A" x 0.10] – "E"	116,741,003 Note: this is the remaining placement capacity under rule 7.1A	